Complex prolactin crosstalk in breast cancer: new therapeutic implications.
The contributions of prolactin (PRL) to breast cancer are becoming increasingly recognized. To better understand the role for PRL in this disease, its interactions with other oncogenic growth factors and hormones must be characterized. Here, we review our current understanding of PRL crosstalk with other mammary oncogenic factors, including estrogen, epidermal growth factor (EGF) family members, and insulin-like growth factor-I (IGF-I). The ability of PRL to potentiate the actions of these targets of highly successful endocrine and molecular therapies suggests that PRL and/or its receptor (PRLR) may be an attractive therapeutic target(s). We discuss the potential benefit of PRL/PRLR-targeted therapy in combination with established therapies and implications for de novo and acquired resistance to treatment.
Carver
Kristopher C
KC
Cellular and Molecular Biology Program, University of Wisconsin-Madison, Madison, WI 53706, USA.
Arendt
Lisa M
LM
Schuler
Linda A
LA
D001943:Breast Neoplasms / Q000378:metabolism* / Q000628:therapy*; D005260:Female; D006801:Humans; D011388:Prolactin / Q000378:metabolism*; D015398:Signal Transduction
D011388:Prolactin